Noonan syndrome (NS) is a congenital autosomic dominant condition characterized by a variable spectrum from a clinical and genetical point of view. Germline mutations in more than ten genes involved in RAS–MAPK signal pathway have been demonstrated to cause the disease. An higher risk for leukemia and solid malignancies, including brain tumors, is related to NS. A review of the published literature concerning low grade gliomas (LGGs) in NS is presented. We described also a 13-year-old girl with NS associated with a recurrent mutation in PTPN11, who developed three different types of brain tumors, i.e., an optic pathway glioma, a glioneuronal neoplasm of the left temporal lobe and a cerebellar pilocytic astrocytoma. Molecular characterization of the glioneuronal tumor allowed to detect high levels of phosphorylated MTOR (pMTOR); therefore, a therapeutic approach based on an mTOR inhibitor (everolimus) was elected. The treatment was well tolerated and proved to be effective, leading to a stabilization of the tumor, which was surgical removed. The positive outcome of the present case suggests considering this approach for patients with RASopathies and brain tumors with hyperactivated MTOR signaling.

Low-grade gliomas in patients with Noonan syndrome: case-based review of the literature / Lodi, M.; Boccuto, L.; Carai, A.; Cacchione, A.; Miele, E.; Colafati, G. S.; Camassei, F. D.; de Palma, L.; de Benedictis, A.; Ferretti, E.; Catanzaro, G.; Po, A.; de Luca, A.; Rinelli, M.; Lepri, F. R.; Agolini, E.; Tartaglia, M.; Locatelli, F.; Mastronuzzi, A.. - In: DIAGNOSTICS. - ISSN 2075-4418. - 10:8(2020), pp. 1-11. [10.3390/diagnostics10080582]

Low-grade gliomas in patients with Noonan syndrome: case-based review of the literature

Cacchione A.;Miele E.;Ferretti E.;Catanzaro G.;Po A.;Agolini E.;Locatelli F.;Mastronuzzi A.
2020

Abstract

Noonan syndrome (NS) is a congenital autosomic dominant condition characterized by a variable spectrum from a clinical and genetical point of view. Germline mutations in more than ten genes involved in RAS–MAPK signal pathway have been demonstrated to cause the disease. An higher risk for leukemia and solid malignancies, including brain tumors, is related to NS. A review of the published literature concerning low grade gliomas (LGGs) in NS is presented. We described also a 13-year-old girl with NS associated with a recurrent mutation in PTPN11, who developed three different types of brain tumors, i.e., an optic pathway glioma, a glioneuronal neoplasm of the left temporal lobe and a cerebellar pilocytic astrocytoma. Molecular characterization of the glioneuronal tumor allowed to detect high levels of phosphorylated MTOR (pMTOR); therefore, a therapeutic approach based on an mTOR inhibitor (everolimus) was elected. The treatment was well tolerated and proved to be effective, leading to a stabilization of the tumor, which was surgical removed. The positive outcome of the present case suggests considering this approach for patients with RASopathies and brain tumors with hyperactivated MTOR signaling.
2020
cancer predisposition; everolimus; mtor signaling; noonan syndrome; pediatric brain tumor
01 Pubblicazione su rivista::01i Case report
Low-grade gliomas in patients with Noonan syndrome: case-based review of the literature / Lodi, M.; Boccuto, L.; Carai, A.; Cacchione, A.; Miele, E.; Colafati, G. S.; Camassei, F. D.; de Palma, L.; de Benedictis, A.; Ferretti, E.; Catanzaro, G.; Po, A.; de Luca, A.; Rinelli, M.; Lepri, F. R.; Agolini, E.; Tartaglia, M.; Locatelli, F.; Mastronuzzi, A.. - In: DIAGNOSTICS. - ISSN 2075-4418. - 10:8(2020), pp. 1-11. [10.3390/diagnostics10080582]
File allegati a questo prodotto
File Dimensione Formato  
Lodi_low-grade gliomas_2020.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 1.28 MB
Formato Adobe PDF
1.28 MB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1449512
Citazioni
  • ???jsp.display-item.citation.pmc??? 13
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 16
social impact